United States Patent |
5,676,977 |
Antelman |
October 14, 1997 |
Method of curing AIDS with tetrasilver tetroxide molecular crystal devices
Abstract
The diamagnetic semiconducting molecular crystal tetrasilver tetroxide (Ag.sub.4 O.sub.4) is utilized for destroying the AIDS virus, destroying AIDS synergistic pathogens and immunity suppressing moieties (ISM) in humans. A single intravenous injection of the devices is all that is required for efficacy at levels of about 40 PPM of human blood. The device molecular crystal contains two mono and two trivalent silver ions capable of "firing" electrons capable of electrocuting the AIDS virus, pathogens and ISM. When administered into the bloodstream, the device electrons will be triggered by pathogens, a proliferating virus and ISM, and when fired will simultaneously trigger a redox chelation mechanism resulting in divalent silver moieties which chelate and bind active sites of the entities destroying them. The devices are completely non-toxic. However, they put stress on the liver causing hepatomegaly, but there is no loss of liver function.
Inventors: |
Antelman; Marvin S. (Rehovot, IL) |
Assignee: |
Antelman Technologies Ltd. (Providence, RI) |
Appl. No.: |
08/658,955 |
Filed: |
May 31, 1996 |
Related U.S. Patent Documents
<td< td=""></td<><td< td=""></td<>
|
|
|
|
|
|
|
Application Number |
Filing Date |
Patent Number |
Issue Date |
|
|
310859 |
Sep., 1994 |
|
|
|
|
|
|
|
|
|
Current U.S. Class: |
424/618 ; 514/495 |
Current International Class: |
A61K 33/38 (20060101); A61K 033/38 () |
Field of Search: |
424/618 514/495 |
United States Patent |
4,647,773 |
Gallo , et al. |
March 3, 1987 |
Method of continuous production of retroviruses (HTLV-III) from patients with AIDS and pre-AIDS
Abstract
A cell system is disclosed for the reproducible detection and isolation of human T-lymphotropic retroviruses (HTLV-family) with cytopathic effects (HTLV-III) from patients with the acquired immune deficiency syndrome (AIDS), pre-AIDS and in healthy carriers. One neoplastic aneuploid T-cell line derived from an adult with lymphoid leukemia, and termed HT, was susceptible to infection with the new variants of HTLV, which are transformed and providing T-cell populations which are highly susceptible and permissive from HTLV-III, and convenience for large scale production, isolation and biological detection of the virus.
Inventors: |
Gallo; Robert C. (Bethesda, MD), Popovic; Mikulas (Bethesda, MD) |
Assignee: |
The United States of America as represented by the Department of Health (Washington, DC) |
[*] Notice: |
The portion of the term of this patent subsequent to May 28, 2002 has been disclaimed. |
Appl. No.: |
06/602,946 |
Filed: |
April 23, 1984 |
Current U.S. Class: |
435/239 ; 424/208.1; 435/235.1; 435/372.3; 435/948 |
Current International Class: |
C12N 5/06 (20060101); C12N 7/00 (20060101); C12N 007/02 (); C12N 007/00 (); C12N 005/00 (); C12R 001/91 () |
Field of Search: |
435/235,239,240,948,5,29 424/89 128/1T |
|
